Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
Type:
Grant
Filed:
April 16, 2021
Date of Patent:
June 2, 2026
Assignee:
INIPHARM, INC.
Inventors:
Joshua Odingo, Heather Kay Webb Hsu, Vincent Florio, Subramanyam Janardhan Tantry, Rajendra Kristam, Athisayamani Jeyaraj Duraiswamy
Abstract: Described herein are hydroxypyridine HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
Type:
Grant
Filed:
October 2, 2023
Date of Patent:
February 18, 2025
Assignee:
INIPHARM, INC.
Inventors:
Sampath Kumar Anandan, Joshua Odingo, Heather Kay Webb Hsu, Vincent Florio, Subramanyam Janardhan Tantry, Athisayamani Jeyaraj Duraiswamy
Abstract: Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such as NAFLD or NASH, or drug induced liver injury (DILI).
Type:
Grant
Filed:
May 10, 2023
Date of Patent:
November 28, 2023
Assignee:
INIPHARM, INC.
Inventors:
Sampath Kumar Anandan, Joshua Odingo, Heather Kay Webb Hsu, Vincent Florio, Subramanyam Janardhan Tantry, Athisayamani Jeyaraj Duraiswamy
© 2026 Justia
